Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 2/20 | 0.54 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.54 |
| ▸ | ACHE | P22303 | 5/20 | 0.50 |
| ▸ | CA1 | P00915 | 4/20 | 0.50 |
| ▸ | CA2 | P00918 | 4/20 | 0.50 |
| ▸ | PKM | P14618 | 1/20 | 0.50 |
| ▸ | DRD2 | P14416 | 3/20 | 0.47 |
| ▸ | DRD3 | P35462 | 3/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8606735 | 0.88 | MTNR1A (0.63) | MTNR1AMTNR1BACHECA1CA2 | |
| SCHEMBL8074296 | 0.88 | MTNR1A (0.63) | MTNR1AMTNR1BACHECA1CA2 | |
| SCHEMBL545767 | 0.88 | MTNR1A (0.63) | MTNR1AMTNR1BACHECA1CA2 | |
| SCHEMBL8076218 | 0.88 | CA1 (0.59) | MTNR1AMTNR1BACHECA1CA2 | |
| SCHEMBL8066286 | 0.88 | CA1 (0.59) | MTNR1AMTNR1BACHECA1CA2 | |
| SCHEMBL8603697 | 0.88 | CA1 (0.59) | MTNR1AMTNR1BACHECA1CA2 | |
| SCHEMBL10225789 | 0.85 | MTNR1A (0.51) | MTNR1AMTNR1BACHECA1CA2 | |
| SCHEMBL9370726 | 0.84 | ALDH1A1 (0.54) | MTNR1AMTNR1BKMT2ACYP19A1TP53 | |
| SCHEMBL12470934 | 0.83 | FAAH (0.59) | — | |
| SCHEMBL2464708 | 0.81 | KMT2A (0.48) | ACHECA1CA2DRD2DRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250289789-A1 | REVERSIBLE LYSINE COVALENT MODIFIERS OF CDK2 AND USES THEREOF | TERREMOTO BIOSCIENCES, INC. | 2025-09-18 | — | — | US | disclosed |
| WO-2025090658-A2 | REVERSIBLE LYSINE COVALENT MODIFIERS OF CDK2 AND USES THEREOF | TERREMOTO BIOSCIENCES, INC. (US) | 2025-05-01 | — | — | WO | disclosed |
| US-9504675-B2 | Alpha-ketoheterocycles and methods of making and using | THE SCRIPPS RESEARCH INSTITUTE (US) | 2016-11-29 | — | — | US | disclosed |
| US-9504675-B2 | Alpha-ketoheterocycles and methods of making and using | THE SCRIPPS RESEARCH INSTITUTE (US) | 2016-11-29 | — | — | US | disclosed |
| EP-2582674-B1 | GPR120 RECEPTOR AGONISTS AND USES THEREOF | CYMABAY THERAPEUTICS INC (US) | 2014-10-01 | — | — | EP | disclosed |
| EP-2582674-B1 | GPR120 RECEPTOR AGONISTS AND USES THEREOF | CYMABAY THERAPEUTICS INC (US) | 2014-10-01 | — | — | EP | disclosed |
| US-20140121246-A1 | GPR120 RECEPTOR AGONISTS AND USES THEREOF | METABOLEX, INC. (US) | 2014-05-01 | — | — | US | disclosed |
| EP-2670245-A1 | ALPHA-KETOHETEROCYCLES AND METHODS OF MAKING AND USING | The Scripps Research Institute (US) | 2013-12-11 | — | — | EP | disclosed |
| US-8598374-B2 | GPR120 receptor agonists and uses thereof | METABOLEX, INC. (US) | 2013-12-03 | — | — | US | disclosed |
| US-8476308-B2 | GPR120 receptor agonists and uses thereof | METABOLEX, INC. (US) | 2013-07-02 | — | — | US | disclosed |
| US-7399774-B2 | 6-substituted nicotinamide derivatives as opioid receptor antagonists | ELI LILLY AND COMPANY (US) | 2008-07-15 | — | — | US | disclosed |
| US-7399774-B2 | 6-substituted nicotinamide derivatives as opioid receptor antagonists | ELI LILLY AND COMPANY (US) | 2008-07-15 | — | — | US | disclosed |
| US-7399774-B2 | 6-substituted nicotinamide derivatives as opioid receptor antagonists | ELI LILLY AND COMPANY (US) | 2008-07-15 | — | — | US | disclosed |
| EP-1613597-B1 | 6-SUBSTITUTED NICOTINAMIDE DERIVATIVES AS OPIOID RECEPTOR ANTAGONISTS | LILLY CO ELI (US) | 2007-11-07 | — | — | EP | disclosed |
| EP-1613597-B1 | 6-SUBSTITUTED NICOTINAMIDE DERIVATIVES AS OPIOID RECEPTOR ANTAGONISTS | LILLY CO ELI (US) | 2007-11-07 | — | — | EP | disclosed |
| US-20060205715-A1 | 6-Substituted nicotinamide derivatives as opioid receptor antagonists | ELI LILLY AND COMPANY | 2006-09-14 | — | — | US | disclosed |
| EP-1613597-A1 | 6-SUBSTITUTED NICOTINAMIDE DERIVATIVES AS OPIOID RECEPTOR ANTAGONISTS | Eli Lilly and Company (US) | 2006-01-11 | — | — | EP | disclosed |
| WO-2004080968-A1 | 6-SUBSTITUTED NICOTINAMIDE DERIVATIVES AS OPIOID RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY (US) | 2004-09-23 | — | — | WO | disclosed |
| US-4939160-A | Nootropic agents | CIBA-GEIGY CORPORATION (US) | 1990-07-03 | — | — | US | disclosed |
| US-4833169-A | MEMORY ACTIVATORS | CIBA-GEIGY CORPORATION (US) | 1989-05-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250289789-A1 | REVERSIBLE LYSINE COVALENT MODIFIERS OF CDK2 AND USES THEREOF | CDK2, CDK20, CDK1 | MTNR1A 2217/4885MTNR1B 1806/4885ACHE 3998/4885 |
| US-20060205715-A1 | 6-Substituted nicotinamide derivatives as opioid receptor antagonists | OPRM1, OPRL1, OPRK1 | MTNR1A 23/4885MTNR1B 25/4885ACHE 1136/4885 |
| US-20140121246-A1 | GPR120 RECEPTOR AGONISTS AND USES THEREOF | GPR119, GPR52, GCGR | MTNR1A 202/4885MTNR1B 165/4885ACHE 4715/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.